Novel peptides derived from neuropeptide Y prevent chemotherapy-induced bone marrow damage by regulating hematopoietic stem cell microenvironment. Issue 5 (3rd September 2018)

• Record Type: Journal Article
• Authors: Park, Min Hee; Baek, Bosung; Jin, Hee Kyung; Bae, Jae-sung
• Is Part Of: Animal cells and systems. Volume 22:Issue 5(2018)
• Page Start: 281
• Page End: 288
• Publication Date: 2018-09-03
• Subjects: Bone marrow damage -- bone marrow microenvironment cells -- Chemotherapy -- hematopoietic stem cell -- neuropeptide Y-derived recombinant peptides; Systems biology -- Periodicals; Biology -- Periodicals; Cytology -- Periodicals; Zoology -- Periodicals; 590
• DOI: 10.1080/19768354.2018.1517826
• Languages: English
• ISSNs: 1976-8354

Abstract

ABSTRACT: Chemotherapy-induced bone marrow damage is accompanied by acute nerve injury in the bone marrow (BM), resulting in sensory and autonomic neuropathy. Cisplatin, a popular chemotherapy drugs, induces the impairment of hematopoietic stem cells (HSCs) and bone marrow regeneration, leading to chronic bone marrow abnormalities. Previously, we reported the protective roles of neuropeptide Y (NPY) against cisplatin-induced bone marrow impairment. In this study, we identified novel peptides, generated from full-length NPY that rescued cisplatin-induced sensory neuropathy and HSC suppression by regulating cell survival in the BM microenvironment. One of these peptides, especially, showed a better protective property against these impairments compared to that seen in full-length NPY. Therefore, we suggest the NPY sequences most effective against the chemotherapy-induced bone marrow dysfunction that could be potentially useful as therapeutic agents for patients receiving chemotherapy.